ComBac-Africa Combating Multidrug-Resistant Gram-Negative Bacteria in Africa through Diagnostic and Antimicrobial Stewardship
- Coordinator
- Universitat Des Saarlandes, Germany
- Runs
- 1 May 2025 to 30 April 2029
- Status
- Running
- EU funding
- €5.9m
- Total cost
- €5.9m
- Partners
- 12 organisations in 7 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101190791
What the project is doing
In the project's own words, from its summary on CORDIS.
Antimicrobial resistance is a major global health threat for humans, animals and the environment, with the highest mortality and morbidity rates in sub-Saharan Africa (SSA). The World Health Organization prioritised several carbapenem- and third-generation cephalosporin-resistant Gram-negative bacteria such as Enterobacterales as the most critical pathogens with only very limited treatment options. Bacteraemia, sepsis and other severe infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) give rise to excess mortality.
Yet, the causative pathogens are rarely identified in patients in SSA due to a lack of microbiological diagnostics. Carbapenems and the new antibiotics ceftazidime-avibactam, cefiderocol and aztreonam-avibactam are active against different MDR GNB and could significantly reduce morbidity and mortality, but they are not widely available in SSA.The ComBac-Africa consortium has the overall goal to improve the management of severe infections due to MDR GNB in Côte d’Ivoire, Guinea-Bissau and Nigeria through the establishment of a needs-adapted diagnostic and antimicrobial stewardship (AMS) programme that provides equitable access to these novel antibiotics for targeted treatment.
This will be achieved through (1) provision of high-quality and accurate microbiological diagnostics for prompt and correct identification of causative agents in bacteraemia and other severe infections; (2) a comprehensive One Health assessment of the epidemiology of GNB in humans, animal and environmental specimens; (3) tailored AMS initiatives, including early outbreak detection and infection prevention measures, to optimise the use of novel antimicrobials; (4) development of clinical algorithms for targeted diagnosis and treatment of infections due to MDR GNB; and (5) establishment of sustainable and affordable access to these antibiotics in SSA.
A clinical trial will assess and quantify the impact of this multi-pronged intervention on patient outcome.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitat Des Saarlandes | Saarbrucken | Germany | Coordinator |
| Fondation Pour Un Centre Suisse De Recherches Scientifiques En Cote D'ivoire | Abidjan | Switzerland | Associatedpartner |
| GARDP Foundation | Geneve | Switzerland | Associatedpartner |
| Schweizerisches Tropen Und Public Health Institut | Allschwil | Switzerland | Associatedpartner |
| Institut Pasteur De Cote D'ivoire | Abidjan | CI | Participant |
| Linq Management GmbH | Berlin | Germany | Participant |
| Ministerio Da Saude Publica | Bissau | GW | Participant |
| Centre for Malaria and Other Tropical Diseases Care, Ilorin | Ilorin | NG | Participant |
| Joseph Sarwuan Tarka University Makurdi | Makurdi | NG | Participant |
| Obafemi Awolowo University | Ile Ife | NG | Participant |
| Instituto Piaget Coop Para O Desenvimento Humano Integral Ecologico Crl | Canelas Vila Nova De Gaia | Portugal | Participant |
| Gardp Africa Npc | Western Cape Cape Town | South Africa | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI